-
Posted by
Two Blokes Jul 29 -
Filed in
Stock
-
3 views
Merck on Tuesday said it will slash $3 billion in costs by the end of 2027 to be fully reinvested to support new product launches and its drug pipeline. The multi-year effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster cancer drug Keytruda in 2028, and braces for the Trump administration's planned tariffs on pharmaceutical imported into the U.S.
